ADVM

Adverum Biotechnologies, Inc. [ADVM] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ADVM Stock Summary

Top 10 Correlated ETFs

ADVM


Top 10 Correlated Stocks

ADVM


In the News

10:36 28 Mar 2024 ADVM

Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

10:46 28 Mar 2024 ADVM

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

03:07 28 Mar 2024 ADVM

Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop

There are plenty of penny stocks ready to pop. However, we have to remember that penny stocks are extremely risky, and can be costly in the end.

06:10 28 Mar 2024 ADVM

Stocks on the Launchpad: The Next 3 Market Sensations

In the current bullish stock market, it's an exhilarating period for savvy investors betting on the upcoming market sensations. The optimism is connected to the S&P 500 shattering the historic 5000 threshold, supported by the U.S. Federal Reserve's bullish projection of 2.9% growth in the first quarter (Q1).

06:15 28 Mar 2024 ADVM

Unleash Massive Returns With These 3 Top Penny Stocks

Despite a recent decline in the leading economic index, the U.S. economy is positioned for a positive future in 2024. Strong employment and robust stock levels contribute to the optimistic outlook.

05:30 28 Mar 2024 ADVM

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47 th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET -

09:47 28 Mar 2024 ADVM

Here's Why You Should Invest in Adverum (ADVM) Stock Now

Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.

04:05 28 Mar 2024 ADVM

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024.

04:05 28 Mar 2024 ADVM

Adverum Biotechnologies to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Adverum Biotechnologies will present at the following upcoming investor conferences:

04:05 28 Mar 2024 ADVM

Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer of Adverum Biotechnologies, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023.

ADVM Financial details

Company Rating
Sell
Market Cap
333.32M
Income
-117.17M
Revenue
3.6M
Book val./share
8.25
Cash/share
9.54
Dividend
-
Dividend %
-
Employees
121
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.74
Forward P/E
-24.43
PEG
-0.07
P/S
25.82
P/B
0.9
P/C
1.54
P/FCF
-1.05
Quick Ratio
4.06
Current Ratio
4.32
Debt / Equity
0.9
LT Debt / Equity
0.77
-
-
EPS (TTM)
-3.27
EPS next Y
-0.6
EPS next Q
-0.15
EPS this Y
644.87%
EPS next Y
-81.75%
EPS next 5Y
-84.2%
EPS last 5Y
63%
Revenue last 5Y
70.48%
Revenue Q/Q
-
EPS Q/Q
609.09%
-
-
-
-
SMA20
-21.54%
SMA50
81.46%
SMA100
64.84%
Inst Own
47.49%
Inst Trans
0.73%
ROA
-64%
ROE
-88%
ROC
-0.78%
Gross Margin
100%
Oper. Margin
-3660%
Profit Margin
-3505%
Payout
-
Shs Outstand
20.75M
Shs Float
14.97M
-
-
-
-
Target Price
2
52W Range
6.81-29.7
52W High
-49.45%
52W Low
+144.33%
RSI
40.27
Rel Volume
0.74
Avg Volume
226.72K
Volume
166.9K
Perf Week
-17.18%
Perf Month
-35.98%
Perf Quarter
22.17%
Perf Half Y
-8.38%
-
-
-
-
Beta
0.873
-
-
Volatility
0.76%, 1.98%
Prev Close
3.6%
Price
14.66
Change
-1.74%

ADVM Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.0800.36
Net income per share
-1.01-1.38-1.48-1.56-11.62
Operating cash flow per share
-0.77-0.93-1.1-1.09-9.06
Free cash flow per share
-1.07-1.07-1.25-1.21-9.14
Cash per share
2.595.053.111.879.57
Book value per share
2.735.13.231.838.28
Tangible book value per share
2.735.13.231.838.28
Share holders equity per share
2.735.13.231.838.28
Interest debt per share
0.50.361.051.057.44
Market cap
7.38B9.23B1.73B575.66M75.92M
Enterprise value
7.35B9.2B1.79B614.03M75.96M
P/E ratio
-114.51-78.55-11.86-3.73-0.65
Price to sales ratio
29.54K0230.06021.09
POCF ratio
-150.18-116.4-16-5.33-0.83
PFCF ratio
-107.93-101.28-14.03-4.8-0.82
P/B Ratio
42.2121.255.463.170.91
PTB ratio
42.2121.255.463.170.91
EV to sales
29.4K0239.24021.1
Enterprise value over EBITDA
-109.76-80.83-12.68-4.08-0.64
EV to operating cash flow
-149.5-116-16.64-5.68-0.83
EV to free cash flow
-107.44-100.93-14.59-5.12-0.82
Earnings yield
-0.01-0.01-0.08-0.27-1.54
Free cash flow yield
-0.01-0.01-0.07-0.21-1.21
Debt to equity
0.180.070.330.590.9
Debt to assets
0.140.060.230.350.43
Net debt to EBITDA
0.50.28-0.49-0.250
Current ratio
9.0620.8214.885.914.13
Interest coverage
00058.790
Income quality
0.760.670.740.70.78
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
113.508.59013.87
Research and developement to revenue
161.68011.89021.52
Intangibles to total assets
00000
Capex to operating cash flow
0.390.150.140.110.01
Capex to revenue
-76.990-2.020-0.22
Capex to depreciation
-12.24-2.85-3.26-1.81-0.14
Stock based compensation to revenue
39.603.3604.88
Graham number
7.8612.5910.38846.53
ROIC
-0.29-0.24-0.28-0.4-0.55
Return on tangible assets
-0.29-0.24-0.33-0.5-0.68
Graham Net
1.844.481.90.590.69
Working capital
156.46M413.57M295.83M158.35M77.86M
Tangible asset value
174.96M434.35M316.19M181.52M83.47M
Net current asset value
128.1M386.22M193.6M63.74M13.23M
Invested capital
0.180.070.330.590.9
Average receivables
002.85M2.85M0
Average payables
2.91M3.46M2.1M1.81M2.08M
Average inventory
00000
Days sales outstanding
00277.8400
Days payables outstanding
0246.67108.99125.13124.23
Days of inventory on hand
00000
Receivables turnover
001.3100
Payables turnover
01.483.352.922.94
Inventory turnover
00000
ROE
-0.37-0.27-0.46-0.85-1.4
Capex per share
-0.3-0.14-0.15-0.12-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.04000
Net income per share
-0.33-0.29-0.31-0.33-2.34
Operating cash flow per share
-0.19-0.22-0.23-0.24-2.11
Free cash flow per share
-0.19-0.22-0.23-0.24-2.13
Cash per share
1.871.641.41.169.54
Book value per share
1.831.571.31.028.25
Tangible book value per share
1.831.571.31.028.25
Share holders equity per share
1.831.571.31.028.25
Interest debt per share
1.890.960.90.757.41
Market cap
575.66M719.18M1.6B1.51B76.21M
Enterprise value
614.03M749.24M1.58B1.49B76.25M
P/E ratio
-4.4-6.19-12.71-11.52-0.8
Price to sales ratio
0199.77000
POCF ratio
-31.16-32.09-68.92-63.35-3.56
PFCF ratio
-30.85-31.97-68.81-62.07-3.53
P/B Ratio
3.174.5612.2214.750.91
PTB ratio
3.174.5612.2214.750.91
EV to sales
0208.12000
Enterprise value over EBITDA
-19.05-26.15-50.18-44.98-3.06
EV to operating cash flow
-33.24-33.43-68.05-62.11-3.56
EV to free cash flow
-32.91-33.3-67.95-60.85-3.53
Earnings yield
-0.06-0.04-0.02-0.02-0.31
Free cash flow yield
-0.03-0.03-0.01-0.02-0.28
Debt to equity
0.590.620.690.740.9
Debt to assets
0.350.350.380.380.43
Net debt to EBITDA
-1.19-1.050.640.90
Current ratio
5.913.633.314.324.13
Interest coverage
-0.4225.2000
Income quality
0.560.770.740.730.9
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
03.55000
Research and developement to revenue
05.85000
Intangibles to total assets
00000
Capex to operating cash flow
0.01000.020.01
Capex to revenue
0-0.02000
Capex to depreciation
-0.11-0.05-0.02-0.33-0.19
Stock based compensation to revenue
01.27000
Graham number
3.683.23.032.7320.85
ROIC
-0.09-0.09-0.11-0.14-0.11
Return on tangible assets
-0.11-0.11-0.13-0.17-0.14
Graham Net
0.590.460.310.230.69
Working capital
158.35M122.4M102.63M95.74M77.86M
Tangible asset value
181.52M157.76M131.16M102.71M83.47M
Net current asset value
63.74M51.05M36.87M30.54M13.23M
Invested capital
0.590.620.690.740.9
Average receivables
00000
Average payables
1.54M2.55M2.14M1.79M2.05M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
117.6585.3518.12129.42171.35
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.761.054.970.70.53
Inventory turnover
00000
ROE
-0.18-0.18-0.24-0.32-0.28
Capex per share
0000-0.02

ADVM Frequently Asked Questions

What is Adverum Biotechnologies, Inc. stock symbol ?

Adverum Biotechnologies, Inc. is a US stock , located in Redwood city of Ca and trading under the symbol ADVM

Is Adverum Biotechnologies, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $2. The lowest prediction is $2 and the highest is $2

What is ADVM stock prediction ?

What is Adverum Biotechnologies, Inc. stock quote today ?

Adverum Biotechnologies, Inc. stock price is $14.66 today.

Is Adverum Biotechnologies, Inc. stock public?

Yes, Adverum Biotechnologies, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap